usdaed

The returns thus far – a staggering sevenfold increase over five years – are merely a prelude, a fleeting glimpse of what may lie ahead. But let us not be seduced by mere numbers. The true measure of an investment is not its past performance, but the anxieties it alleviates, the vulnerabilities it addresses. And Vertiv, my friends, addresses a vulnerability of profound consequence. A failure of cooling is not simply a technical malfunction; it is a collapse of ambition, a stifling of progress. It is a return to the darkness.

NuScale, they say, promises a revolution. A way to shrink the monstrous appetite of energy demand into manageable portions. To build power not in monolithic fortresses of concrete and steam, but in discreet, transportable modules, as if one could simply ship a sunbeam to a darkened corner of the world. The notion is seductive, especially in an age where data centers, those insatiable digital gods, demand ever more sustenance. These centers, humming with the ghosts of forgotten conversations and the feverish calculations of algorithms, require a power source as relentless and unforgiving as the logic that governs them. And NuScale, for a time, appeared to be that source.

They’re already leading the charge on this AI thing, which is good. Being a leader is important. It’s just… leadership needs to translate into actual, you know, revenue. And that’s where things get interesting. I mean, they have all the pieces. It’s just…are they going to use them? It’s a bit like having a really talented chef and then just ordering takeout every night.

They speak of ‘investing for the long term,’ twenty years they say. As if time itself were a reliable partner, not a relentless thief. But let us indulge this fancy, for a moment. Let us consider Eli Lilly, not as a beacon of innovation, but as a particularly well-maintained machine, grinding away at the problem of human frailty. A machine, I might add, increasingly reliant on these…digital assistants.

They did the stock split thing in November, which is supposed to signal ‘good times ahead!’ but clearly, the market didn’t get the memo. It’s not like they haven’t been trying. Three quarterly reports that landed with a thud. Each one a little more… underwhelming. But that’s not the full story, is it?

Which of these, then, presents the more rational prospect for investment as we approach 2026? Let us proceed with caution, dissecting the illusions that cling to each.

Now, I’m not saying this stock is a guaranteed get-rich-quick scheme – if you’re looking for that, I suggest investing in carrier pigeons. But I am saying it deserves a closer look, especially after this little dip. So, let’s get down to brass tacks, shall we? Here are three reasons why I think you should consider adding Abbott Labs to your portfolio, before the market remembers what a good company this is.